Aflibercept/nesvacumab

Drug Profile

Aflibercept/nesvacumab

Alternative Names: Aflibercept/Ang2-antibody; Ang2 antibody/Eylea; Ang2-antibody/aflibercept; Eylea/Ang2-antibody; Eylea/nesvacumab; Nesvacumab/aflibercept; Nesvacumab/Eylea; REGN 910-3; REGN-910/Eylea

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Eye disorder therapies; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Angiopoietin-2 inhibitors; Placenta growth factor inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic macular oedema; Wet age-related macular degeneration

Most Recent Events

  • 03 Oct 2017 Regeneron Pharmaceuticals completes the phase II ONYX trial in Wet age-related macular degeneration (In adults, In the elderly) in USA (Intravitreous) (NCT02713204)
  • 10 Jul 2017 Regeneron completes the phase II RUBY trial in Diabetic macular oedema in USA (Intravitreous) (NCT02712008)
  • 10 Feb 2017 Regeneron completes enrolment in the ONYX trial in Wet-age related macular degeneration in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top